Acifran

CAS# 72420-38-3

Acifran

Catalog No. BCC7170----Order now to get a substantial discount!

Product Name & Size Price Stock
Acifran: 5mg $81 In Stock
Acifran: 10mg Please Inquire In Stock
Acifran: 20mg Please Inquire Please Inquire
Acifran: 50mg Please Inquire Please Inquire
Acifran: 100mg Please Inquire Please Inquire
Acifran: 200mg Please Inquire Please Inquire
Acifran: 500mg Please Inquire Please Inquire
Acifran: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Acifran

Number of papers citing our products

Chemical structure

Acifran

3D structure

Chemical Properties of Acifran

Cas No. 72420-38-3 SDF Download SDF
PubChem ID 51576 Appearance Powder
Formula C12H10O4 M.Wt 218.21
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble in DMSO > 10 mM
Chemical Name 5-methyl-4-oxo-5-phenylfuran-2-carboxylic acid
SMILES CC1(C(=O)C=C(O1)C(=O)O)C2=CC=CC=C2
Standard InChIKey DFDGRKNOFOJBAJ-UHFFFAOYSA-N
Standard InChI InChI=1S/C12H10O4/c1-12(8-5-3-2-4-6-8)10(13)7-9(16-12)11(14)15/h2-7H,1H3,(H,14,15)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Acifran

DescriptionHypolipidemic agent. Exhibits higher potency than nicotinic acid and clofibrate. Full and potent agonist at the human orphan GPCR HM74A/GPR109A and GPR109B (EC50 values are 1.3 and 4.2 μM respectively). Reduces serum triglycerides and circulating LDL-cholesterol in vivo, without affecting liver weight or liver enzymes.

Acifran Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Acifran Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Acifran

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 4.5827 mL 22.9137 mL 45.8274 mL 91.6548 mL 114.5685 mL
5 mM 0.9165 mL 4.5827 mL 9.1655 mL 18.331 mL 22.9137 mL
10 mM 0.4583 mL 2.2914 mL 4.5827 mL 9.1655 mL 11.4569 mL
50 mM 0.0917 mL 0.4583 mL 0.9165 mL 1.8331 mL 2.2914 mL
100 mM 0.0458 mL 0.2291 mL 0.4583 mL 0.9165 mL 1.1457 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Acifran

Acifran: a double-blind, randomized, placebo-controlled efficacy study in type IIa hyperlipoproteinemic patients.[Pubmed:3314798]

Artery. 1987;14(6):338-50.

The antihyperlipoproteinemic agent Acifran (AY-25,712) was administered double-blind to 14 Type IIa hyperlipoproteinemic patients for 12 weeks in dosages of 100 mg t.i.d. or 300 mg t.i.d. An additional seven patients received placebo. Fasting plasma lipid and lipoprotein concentrations were determined at baseline (mean of 3 values), Week 8 (mean of 6- and 8-Week values), and Week 12 (mean of 10- and 12-Week values). At Week 8, patients receiving Acifran 100 mg t.i.d. showed low-density lipoprotein (LDL) cholesterol levels which were 13% lower than pretreatment baseline (p less than 0.01) and 14% lower than patients given placebo (p less than 0.05); high-density lipoprotein (HDL) cholesterol levels were 11% higher compared with either baseline or the placebo group (p less than 0.05); the LDL/HDL ratio was 20% lower than baseline (p less than 0.001) and 21% lower than the placebo group (p less than 0.05); total cholesterol was 8% lower than that of the placebo group (p less than 0.05). There was no apparent relationship between changes in plasma lipid concentrations and Acifran dose or treatment duration except for triglycerides, which at Week 12 were 25% lower than baseline (p less than 0.001) and 35% lower than the placebo group (p less than 0.05) only in the Acifran 300 mg t.i.d. group, in which HDL-cholesterol was concurrently 18% higher compared with placebo (p less than 0.05). In this 12-week study Acifran provided safe and effective treatment for Type IIa hyperlipoproteinemia.

Pharmacokinetics and disposition of the lipid-lowering drug acifran in normal subjects and in patients with renal failure.[Pubmed:2295219]

Clin Pharmacol Ther. 1990 Jan;47(1):50-6.

The pharmacokinetics and metabolic fate of the antihyperlipidemic drug Acifran were assessed after a single oral dose of the 14C-labeled drug to healthy male volunteers. Peak serum Acifran and radioactivity concentrations were attained 1 to 2 hours after dosing, and the drug was eliminated with a half-life of 1.6 hours. Virtually all of the recovered dose was excreted in the urine. All of the serum and urinary radioactivity was caused by unconjugated Acifran. In patients with moderate chronic renal failure, the binding of Acifran to plasma proteins was decreased, and the plasma concentrations of total and unbound drug were greater than those of healthy subjects. Renal failure substantially reduced the plasma and renal clearance of total and particularly of unbound Acifran, moderately reduced its volume of distribution, and increased its elimination half-life from 1.4 to 1.7 hours to 5.7 hours. The results show that Acifran is very well absorbed, is rapidly eliminated, is excreted in the urine, and does not undergo any detectable biotransformation in healthy human subjects.

Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b.[Pubmed:17358052]

J Med Chem. 2007 Apr 5;50(7):1445-8.

Recently identified GPCRs, GPR109a and GPR109b, the high and low affinity receptors for niacin, may represent good targets for the development of HDL elevating drugs for the treatment of atherosclerosis. Acifran, an agonist of both receptors, has been tested in human subjects, yet until recently very few analogs had been reported. We describe a series of Acifran analogs prepared using newly developed synthetic pathways and evaluated as agonists for GPR109a and GPR109b, resulting in identification of compounds with improved activity at these receptors.

Triglyceride modulation by acifran analogs: activity towards the niacin high and low affinity G protein-coupled receptors HM74A and HM74.[Pubmed:16389067]

Biochem Biophys Res Commun. 2006 Feb 10;340(2):482-90.

Niacin is known to exert profound beneficial effects on cholesterol levels in humans, although its use is somewhat hampered by the gram quantities necessary to exert effects and the prevalence of compliance-limiting skin flushing side effects that occur. Recently, two G protein-coupled receptors (GPCRs) for niacin were identified and characterized as high (HM74A; GPR109A) and low (HM74; GPR109B) affinity receptors based on the binding affinities of niacin. These receptors also bind Acifran (AY-25,712), which is known to modulate lipid levels like niacin, with similar affinities. Twelve analogs of Acifran were chemically synthesized. One analogue demonstrated a dose-dependent decrease in serum triglycerides in rats within 3h of oral administration. Next, the Acifran analogs were assessed for their activity towards the high and low affinity niacin receptors expressed in CHO-K1 cells. Constructs expressing HM74A or HM74 were stably transfected into CHO-K1 cells and shown to elicit phosphorylation of p42 and p44 mitogen-activated protein kinase (ERK1/ERK2) phosphorylation upon addition of niacin or Acifran. The presence of functionally coupled GPCRs was further confirmed using Pertussis toxin, which completely inhibited the ability of either niacin or Acifran to elicit phospho-ERK1/ERK2. The EC(50) of p-ERK1/ERK2 for niacin for the high and low affinity receptors was 47nM and indeterminate (i.e., >100microM), respectively, while the EC(50) for Acifran was 160 and 316nM, respectively. Two chemical analogs of Acifran demonstrated robust phosphorylation of ERK1/ERK2. Collectively, these data suggest that the synthesis of Acifran analogs may be a suitable path for developing improved HM74A agonists.

Keywords:

Acifran,72420-38-3,Natural Products,Hydroxycarboxylic Acid Receptors, buy Acifran , Acifran supplier , purchase Acifran , Acifran cost , Acifran manufacturer , order Acifran , high purity Acifran

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: